EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.
EQS-News: Evotec SE / Key word(s): Annual Results Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth 24.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement.
Dr Mario Polywka, Interim Chief Executive Officer of Evotec: “Evotec’s business displayed great resilience in a challenging market environment. Our central focus for 2024 is to protect our strong balance sheet and refocus the Company on profitable growth. Through the planned priority reset and measures to rightsize our operational and corporate structure, we are taking the necessary steps to ensure that we continue to work with our partners to shape the medicines that matter for many years to come.” Key figures of consolidated income statement & segment information Evotec SE & subsidiaries
1) Adjusted for exchange rate effects of € 13.8 m, Group revenues would have amounted to € 795.2 m. 2) Includes unpartnered R&D expenses of € 64.8 m in 2023 (2022: € 70.2 m). 3) Before changes in contingent consideration, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result.
FINANCIAL PERFORMANCE Resilience in a challenging year Broader and deeper strategic alliance with Bristol Myers Squibb (BMS) Focusing on sustainable and profitable growth The Company plans to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Date: Wednesday, 24 April 2024 To join the audio webcast and to access the presentation slides, please register via this link.
24.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | [email protected] |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1887593 |
End of News | EQS News Service |
|
1887593 24.04.2024 CET/CEST